These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 3093202)

  • 1. Long-term bromocriptine therapy and predictive tests in acromegaly.
    Karashima T; Kato K; Nawata H; Ikuyama S; Ibayashi H; Okamura K; Shiroozu A; Nakashima T; Fujishima M
    Endocrinol Jpn; 1986 Apr; 33(2):163-7. PubMed ID: 3093202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contradictory clinical implications between paradoxical growth hormone responses to thyrotropin-releasing hormone and those to vasoactive intestinal peptide and luteinizing hormone-releasing hormone in acromegaly.
    Watanobe H; Tamura T; Sasaki S; Takebe K
    Neuropeptides; 1993 Dec; 25(6):363-75. PubMed ID: 8127416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly.
    Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ; Liuzzi A
    Acta Endocrinol (Copenh); 1983 Aug; 103(4):446-50. PubMed ID: 6310918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in plasma GH levels and clinical activity during bromocriptine therapy in acromegaly. The value of predictive tests.
    Nortier JW; Croughs RJ; Donker GH; Thijssen JH; Schwarz F
    Acta Endocrinol (Copenh); 1984 Jun; 106(2):175-83. PubMed ID: 6145276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioactive GH-like immunoglobulins G in active acromegaly: response to long-term treatment with bromocriptine.
    Campino C; Szecowka J; Lopez JM; Seron-Ferre M
    Clin Endocrinol (Oxf); 1995 Jul; 43(1):111-6. PubMed ID: 7641402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Response of growth hormone to sandostatin and bromocriptine and prognostic value of prolactin levels in serum and thyroliberin test in patients with active acromegaly].
    Gasińska T; Nowak S
    Endokrynol Pol; 1993; 44(4):455-65. PubMed ID: 8055814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of plasma prolactin levels in the prediction of the responsiveness of growth hormone secretion to bromocriptine and TRH in acromegaly.
    Lamberts SW; Liuzzi A; Chiodini PG; Verde S; Klijn JG; Birkenhäger JC
    Eur J Clin Invest; 1982 Apr; 12(2):151-5. PubMed ID: 6807686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination therapy with bromocriptine and cyproheptadine in patients with acromegaly.
    Hanew K; Sugawara A; Shimizu Y; Sato S; Sasaki A; Tazawa S; Ishii K; Saitoh T; Saso S; Yoshinaga K
    Endocrinol Jpn; 1989 Jun; 36(3):429-38. PubMed ID: 2510991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No acute effect of pimozide on the plasma GH levels in acromegaly.
    Nortier JW; Croughs RJ; Donker GH; Thijssen JH; Schwarz F
    Acta Endocrinol (Copenh); 1983 Aug; 103(4):461-8. PubMed ID: 6613492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH/prolactin-containing pituitary adenomas.
    Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ
    J Clin Endocrinol Metab; 1985 Jun; 60(6):1148-53. PubMed ID: 3923021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex.
    van der Lely AJ; Harris AG; Lamberts SW
    Clin Endocrinol (Oxf); 1992 Aug; 37(2):181-5. PubMed ID: 1395069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation.
    Oppizzi G; Petroncini MM; Dallabonzana D; Cozzi R; Verde G; Chiodini PG; Liuzzi A
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1348-53. PubMed ID: 2878007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential response to aminergic stimuli and biological behavior of growth hormone secreting pituitary adenomas.
    Fanghanel G; Larraza O; Villalobos M; Fanghanel L; Velasco M; Velasco F
    Can J Neurol Sci; 1990 Feb; 17(1):78-82. PubMed ID: 2107017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bromocriptine does not alter growth hormone (GH) responsiveness to GH-releasing hormone in acromegaly.
    Cozzi R; Dallabonzana D; Oppizzi G; Verde G; Liuzzi A; Chiodini PG
    J Clin Endocrinol Metab; 1986 Mar; 62(3):601-4. PubMed ID: 3080469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the acute administration of haloperidol and pimozide on plasma GH levels in acromegaly.
    Carmina E; Lo Coco R; Lanzara P; Jannì A
    Acta Endocrinol (Copenh); 1979 Aug; 91(4):609-15. PubMed ID: 115193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of the dopamine agonist lisuride in the treatment of acromegaly and pathological hyperprolactinemic states.
    Verde G; Chiodini PG; Liuzzi A; Cozzi R; Favales F; Botalla L; Spelta B; Dalla Bonzana D; Rainer E; Horowski R
    J Endocrinol Invest; 1980; 3(4):405-14. PubMed ID: 6782153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The higher the growth hormone response to growth hormone releasing hormone the lower the response to bromocriptine and thyrotrophin releasing hormone in acromegaly.
    Smals AE; Pieters GF; Smals AG; Hermus AR; Benraad TJ; Kloppenborg PW
    Clin Endocrinol (Oxf); 1987 Jul; 27(1):43-7. PubMed ID: 3115634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal growth hormone responses to CB-154 and thyrotropin-releasing hormone (TRH) in patients with acromegaly.
    Hanew K; Aida M; Sasaki A; Mouri T; Yoshinaga K
    Tohoku J Exp Med; 1979 Jan; 127(1):53-62. PubMed ID: 104407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of bromocriptine on serum levels of growth hormone and other pituitary hormones and its metabolic effects in active acromegaly.
    Roelfsema F; Goslings BM; Frölich M; Moolenaar AJ; Seters AP; Van Slooten H
    Clin Endocrinol (Oxf); 1979; 11(2):235-44. PubMed ID: 114344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in growth hormone (GH) secretion induced by human pancreatic GH releasing hormone-44 in acromegaly: a comparison with thyrotropin-releasing hormone and bromocriptine.
    Chiodini PG; Liuzzi A; Dallabonzana D; Oppizzi G; Verde GG
    J Clin Endocrinol Metab; 1985 Jan; 60(1):48-52. PubMed ID: 3917270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.